Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yes I know they have treated a few patients (among Thermo's brother if I recall correctly) with Direct which looked very promising.
However, since Direct is NOT an active trial worse there is no other active trial at present with NWBO and the data from the few single Direct patients are insufficient to prove any statistical medical evidence one can not call it a platform yet. This is entirely NWBO's choice.
So theoretically there could be a platform however in practice there is none. (IMO) the reactivating of the platform is up to the acquiring company buying NWBO, they have all patents in place todo so.
because it is apparently such an emotional subject I have decided to once and for all prove my point see tradingview chart:
1. From Jan - 1/2 march 2021 nwbo and XBI performed in the same manner
2. From 1/2 march 2021 - aug 2021 NWBO outperformed XBI.
3. From Aug 2021 - 1/2 Nov 2021 NWBO and XBI performed on average in the same manner
4. From 1/2 nov - end dec. NWBO declined worse than XBI thus NWBO underperformed XBI
5. Jan - Feb 9 NWBO increased from a worse position while XBI decreased
6. and now XBI and NWBO have paired up again.
So over the course of the last 12 months, NWBO and XBI performed the same for investors. If you would have invested $ 1000 in NWBO and in XBI on Jan 1 2021 and compared it with today you would not have been worse or better off by one or the other. Which is my whole point
It is normal to measure the last 12 months, not a timeframe a subjective investor would like to observe to fit its biased narrative.
The only treatment NWBO is after getting approved is for GBM. Thats it.
If they want approval for lung, colon, pancreatic, liver, ovarian, head and neck, and others for all Types of Inoperable Solid tumors they will have to conduct trials.
Facts:
If you think that LP will on her blue eyes just gain approval for anything outside GBM after GBM data without conducting new trials then I cant help you. Ofcourse new trials need to be started to prove there is a platform.
No NWBO SP did NOT outperform the XBI benchmarked it has now paired up after it first underperformed.
NWBO journal article is late due to peer review back and forwards which is taking way longer than usual with other medical journal publications.
Im measuring it from the decline of biotech and you from the beginning of the year which is highly arbitrarily.
NWBO has caught up with XBI which before that had lacked behind with, great. If it now overtakes XBI then we are doing better.
Its called the measurement of the bench market.
https://www.investopedia.com/articles/investing/032516/how-use-benchmark-evaluate-portfolio.asp
yes on paper, in reality, a biotech has to prove that by conducting other trials than the main one. NWBO is not conducting any trials at present and thus until they do they are not developing their MOA outside GBM, their platform. If tomorrow they would announce they have continued any of their discontinued Direct trials then yes then from that moment on they are developing a platform by trying to prove the MOA works outside GBM. Now they have no platform only a GBM treatment.
NWBO has declined more than the XBI over the last 6 months prior to dec 31 and has now since the start of the year caught up, that's no progress that's making up for lost ground towards XBI since the decline of small biotech 6 months ago.
Now XBI and NWBO have the same decline -26% and thus the same performance. Its really not that difficult.
NWBOs GBM trial data will show that they knocked the ball out of the park I have zero doubt about that.
They dont have a platform. They only have a platform in name and on paper. They have a platform when they actually run more trials on the same MOA of the drug outside GBM
They only have a successful Phase 3 trial for the treatment of GBM that's, not a platform.
you are misinformed NWBO is NOT crushing XBI.
Jeez NWBO gains of what it lost before more than the XBI did over the last 6 months, how difficult is that for you? If don't understand simple math dont respond.
it all depends on the small biotech index which NWBO lacks behind. XBI up 5% NWBO 2%. Without news I dont see NWBO beating XBI. If small biotech craters NWBO goes down as well H and S or not.
you really have to come up with something more original and new ex this is a lousy come back from a two-week absence on an announced and promised farewell. At least try to be original when trying to be snapy and stop repeating your tired old mantra of lock her up lock her up
I can assure you that big shareholders are speaking with Less Goldman a lot and occasionally with LP as well. The first is blathering as much BS as DI.
yes I know that and what they have stated here:
lol if you demand from each poster here written and signed proof from LP before you believe anything you might as well stop reading Ihub. In case you haven't noticed we dont get anything from NWBO officially what the heck is going on so we are all puzzling the pieces. Your argument that I don't have bulletproof evidence is therefore laughable no one has and you don't have proof that the obvious delay you have admitted there i, is only Covid related.
You can't prove the delay is Covid so your argument that is the reason for the delay is nonsense. Proof the delay is only Covid if you cant then its peer review process related.
hoffman, DI has stated last November that they are in the peer-reviewing process. After he said they are being delayed (email Mike).
The only conclusion is thus that are stuck in peer-reviewing.
Also like I have said previously read sentiments and more important Vubru's posts from this week. Vubru has a lot of experience with the publication of medical articles in journals. He has said how long a normal peer review would take a timeline they have now widely crossed. The only conclusion there is to make is that thus they have run into problems in that process.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167713346
thank you FeMike for sharing
It cant get more factual than this sorry to hear you won't even believe the spokesmen of NWBO DI.
funny its not a pissing contest and yet you could not help yourself attacking my post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167742113
not addressed to you with your same iterated narrative?
They are late with the publication they said so themself, that doesn't mean that the results won't be stunning they will be. They have made many and keep making many mistakes they are not our lord and savior. Why don't you start attacking Flipper he is as critical towards NWBO as I am perhaps even more?
I know I was just trying to be funny but I am serious about the 87 year old. The point is that I as you seriously believe that a few peer reviewers are being a pain in the buts here and NWBO should then pull the journal and publish in JTM tomorrow.
Its all about egos, the FDA does not care if and where it was published.
I think that too and I agree
I agree, preaching to the choir, its beyond absurd.
Its not only obscure behavior towards long loyal shareholders its also and even more so needlessly increasing the suffering of GBM patients.
I a, now starting to believe there is a longer-lasting problem with the journal. But then for God's sake publish it in a less prestigious journal. Its all about egos at this point.
wow this is the first time I see a more critical post from you towards the company. And that is saying something
ok no Disney fan suit yourself (ps dont take yourself so seriously for peet sake)
It is really absolutely exciting Advent is being built out to be able to cater to more GBM patients. I however think its beyond unethical to keep offering medical relief to desperate GBM patients without them knowing for sure if the treatment is efficient for they have not seen topline.
Imagine you are a GBM patient and you have a life or death decision to make with your last $200k... yes sure we can all stand on the sidelines saying we know topline will be great, what it will indeed be, but if your a patient and your life and last monetary resources depend on it the pressure without is immense for you medical doctor will tell you for sure: look if you do that ok but the outcome is still unknown.
I find every day NWBO offering DCVAX L to patients without disclosing trial results unethical. The one-year rule is not for nothing.
apparently, we have become so desperate to now put our hopes of disclosing topline data in the hands of the president. I am betting next we will be looking for tea leaves in the new Snow white Disney movie releasing mid-July 2022.
100% agree
ok thanks Flipper we will have to wait and see what they will come up with this century
you are right about that.
On the other hand, would they have back then known that in May 2021 the WHO would change the definition of GBM?
wow what happened with Anavex today it reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial and still got slammed down.
Just comes to show how bizarre the market is slamming down biotechs on positive topline data nowadays. Anavex is not the only biotech going through this. From my perspective, this is what would have happened with Northwest if they would have "only" reported positive topline data without a journal.
heck what will this market environment mean for NWBO SP after the journal?